WHO Trial Finds Remdesivir Has 'No Meaningful Effect' In COVID-19 Patients
The medicine is one of the few to win regulatory approval as a treatment for the disease, but has fallen out of favor with the health authority.
Full Article
WHO Trial Finds Remdesivir Has 'No Meaningful Effect' In COVID-19 Patients
NPR
0 shares
1 views
You might like
Related news coverage
Humanigen showing positive results for cancer drug lenzilumab, also used to treat patients hospitalized with coronavirus
Proactive Investors
Key drug candidate lenzilumab is a recombinant monoclonal antibody Designed to reduce sometimes dangerous side effects associated..
-
WHO warns against remdesivir for COVID-19 treatment
Mid-Day
-
WHO advises against use of Gilead’s remdesivir for COVID-19 treatment
Proactive Investors
-
'Dangerous to rely on alternative medicine', warn health experts
Mid-Day
-
Humanigen showing positive results for lenzilumab drug to treat patients hospitalized with COVID-19
Proactive Investors
Advertisement
More coverage
Humanigen showing positive interim Phase 3 results for lenzilumab to treat patients hospitalized with COVID-19
• The company's key drug candidate is lenzilumab, a recombinant monoclonal antibody • Conducting a Phase 3 clinical trial for..
Proactive Investors
Humanigen announces positive interim Phase 3 data on lenzilumab to treat patients hospitalized with COVID-19
Humanigen Inc (NASDAQ:HGEN) (FRA:0KB2) announced Friday positive interim Phase 3 data on lenzilumab to treat patients hospitalized..
Proactive Investors